Webinars Archives - Page 4 of 32 - BioProcess InternationalBioProcess International

Purification of DNA Oligonucleotides Using Anion Exchange Chromatography

This webcast features: William H. Rushton, Process Chromatography Support Scientist, Bio-Rad Laboratories. DNA oligonucleotides obtained by solid-phase synthesis contain incomplete or erroneous sequences that require removal for the advancement of these molecules as therapeutics. These key impurities in crude samples are length-based and are best removed by anion exchange chromatography. In this webcast, data will be presented using Nuvia HP-Q Resin, a high-performance strong anion exchanger, used for the purification of two oligonucleotides (20-mer and 21-mer) having a phosphodiester backbone.…

Development of LentiVEX™ Packaging and Producer Cell Lines for Lentivirus Manufacture

by BPI Contributor

This webcast features: Corinne Branciaroli, Group Leader, CLD Viral Manufacturing, OXGENE, a WuXi Advanced Therapies Company. Lentiviral (LV) vectors have significant potential for cell and gene therapy applications. CAR-T and TCR therapies are becoming established treatments for blood malignancies that don’t respond to current therapies, and novel research aims to also exploit the usage of LV vectors to target solid tumors. However, challenges remain within the LV vector manufacturing process, such as achieving scalability and robustness. These challenges contribute to…

Next Generation PATfixTM Software

by BPI Contributor

This webcast features: Blaž Goričar, Process Analytics Development Manager, BIA Separations, now a Sartorius company. Process development and production of gene therapy products brings together people with different skills and specializations, hence PATfixTM software is built to address the needs and solve challenges of each. An integral part of the PATfixTM value proposition, the PATfixTM software strips away the complexity of chromatography at the day-to-day operational level, while retaining it for higher level tasks. Analytical chromatography is rapidly gaining supremacy…

A Flexible Intensified Seed Train to Boost Biopharma Productivity

by BPI Contributor

This webcast features: Yuliya Mikhed, PhD, Product Manager, Biostat® RM Bioreactors & Matthew Houser, Product Manager, Biostat STR®, Sartorius. Biopharma manufacturers need adaptable, efficient facilities that support varied products and production demands. Process intensification (PI) and perfusion processes can help meet these challenges. In this webinar, Sartorius experts present the latest PI technologies, including advanced Biostat® bioreactors integrated with PAT functionality controlled by the Biobrain® automation platform. Key Takeaways: Discover Biostat® RM, Biostat® STR, and Biobrain® automation. Explore the flexible…

Maximizing Performance of Your Biologics Pipeline: Media and Process Optimization Using Cutting-Edge Tools

by BPI Contributor

This webcast features: Yaron Silberberg, PhD, Chief Scientist, Ajinomoto Genexine. Cell culture media composition and upstream bioprocess conditions are crucial factors affecting productivity in the production of biotherapeutics. In recent years, advanced techniques using IT approaches, including computer simulation of bioprocesses, AI and multi-omics methods for analysis of cellular metabolic pathways, allow optimization of both process and media composition for maximizing protein production and process productivity. In this webinar, a quick overview of biologics production and the importance of cell…

Improving Gene Therapy Viral Vector Manufacturing Economics: Modelling Bioprocess Costs

by BPI Contributor

This webcast features: Emmanuelle Cameau, Strategic Technology Partnership Leader, Cell and Gene Therapy, Pall Corporation & Maxime Dumont, Cell & Gene Therapy Product Manager, Polyplus-transfection. Gene therapy viral vector manufacturers strive to reduce time to market and cost per dose to ensure treatment affordability and patient access. Approved and commercialized AAV-based gene therapies Luxturna® and Zolgensma®, for patients suffering from vision loss and spinal muscular atrophy, are the first of many gene therapies that are expected to reach the market…

Stability Assessment of mRNA Formulations – Toward the Development of Degradation Assays for mRNA-based Vaccines

by BPI Contributor

This webcast features: Caio Henrique Barros, PhD, Research Scientist, National Institute for Bioprocessing Research and Training & James Geiger, PhD, Field Application Scientist, PerkinElmer. The COVID-19 pandemic has demonstrated the potential of mRNA vaccines to protect against infectious diseases. These unprecedented circumstances have also highlighted the instability of the mRNA molecule, which required the first COVID vaccines to be distributed at ultracold temperatures. This limitation has intensified efforts to develop mRNA formulations that are sufficiently stable at room temperature. Dried…

Ask the Expert: Using Monolith-Based Chromatography to Monitor In Vitro Transcription Reactions

by Rok Sekirnik

In vitro transcription (IVT) is a critical step in messenger RNA (mRNA) production. In a March 2022 webinar, Rok Sekirnik (head of process development for mRNA and plasmid DNA (pDNA) applications at BIA Separations, part of Sartorius) explained that optimizing concentrations of reagents used during IVT helps to maximize the amount of mRNA that is produced. Drug developers have great need for analytical methods that can measure IVT in real time. Sekirnik showed how CIMac PrimaS monolith chromatography columns enable…

High Performance With GMP Ready CHT Prepacked Process-Scale Columns

by BPI Contributor

This webcast features: Khaled S. Mriziq, PhD, Senior Marketing Manager, Process Chromatography, Bio-Rad Laboratories. In this webinar, we will present performance data for the newly launched, GMP ready CHT™ Ceramic Hydroxyapatite prepacked process-scale columns. This will include HETP and asymmetry data that shows excellent column performance and shipping stability over a range of column diameters. The columns are designed to eliminate any headspace formation during transportation. Cycling and pressure data will also be presented. Foresight Pro Columns can be used…

Bridging Anti-CHO HCP Antibodies From Two Third Generation Cygnus CHO HCP ELISA Kits by AAE-MS™

by BPI Contributor

This webcast features: Eric Bishop, Vice President, Research & Development, Cygnus Technologies. A well-developed, broadly reactive, and qualified HCP ELISA remains a gold standard method effectively used during the purification process to ensure removal of HCP and to demonstrate process consistency and final drug substance purity. Regulatory guidelines require that sponsors use orthogonal methods for demonstrating antibody coverage to individual HCPs and provide a comprehensive assay qualification package to ensure the HCP ELISA is fit for purpose. In this presentation,…